检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:姜立东[1]
出 处:《中国实用医药》2017年第4期119-120,共2页China Practical Medicine
摘 要:目的探讨洛铂与顺铂联合氟尿嘧啶在胃肠道肿瘤肝转移介入治疗中的临床应用价值。方法选取40例胃肠道肿瘤肝转移患者作为研究对象,按照治疗方法的不同分为洛铂组(洛铂联合氟尿嘧啶治疗)和顺铂组(顺铂联合氟尿嘧啶治疗),各20例。分析胃肠道肿瘤肝转移扫描情况分析,并评价比较两组患者的临床疗效。结果 40例患者的胃肠道肿瘤肝转移扫描情况分析:其中胃癌患者23例,不染色4例(17.4%),较均一染色7例(30.4%),边缘环状染色12例(52.2%);大肠癌17例,不染色3例(17.6%),较均一染色6例(35.3%),边缘环状染色8例(47.1%)。洛铂组患者的总有效率为40%,高于顺铂组的10%,差异具有统计学意义(P<0.05)。结论洛铂联合氟尿嘧啶联合治疗胃肠道肿瘤效果确切,值得临床推广。Objective To investigate clinical application value of lobaplatin and cisplatin combined with fluorouraeil in interventional therapy for liver metastasis of gastrointestinal tumor. Methods A total of 40 patients withiiver metastasis of gastrointestinal tumor as study subjects were divided by different treatment measures into lobaplatin group (lobaplatin combined with fluorouracil for treatment) and cisplatin group (cisplatin combined with fluorouracil for treatment), with 20 cases in each group. Analysis was made on scanning status in liver metastasis of gastrointestinal tumor, and clinical effects were evaluated and compared between the two groups. Results Scanning status in liver metastasis of gastrointestinal tumor in 40 patients showed 23 cases with stomach cancer, 4 cases without staining (17.4%), 7 eases with uniform staining (30.4%) and 12 cases with edge ring-staining (52.2%); and 17 cases with coloreetal cancer, 3 cases without staining (17.6%), 6 cases with uniform staining (35.3%) and 8 cases with edge ring-staining (47.1%). The lobaplatin group had higher total effective rate as 40% than 10% in the cisplatin group, and their difference had statistical significance (P〈0.05). Conclusion Combination of lobaplatin and fluorouracil shows precise effect in treating patients with gastrointestinal tumor, and this method is worth clinical promotion.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.118.19.89